{"id":448812,"date":"2021-03-02T16:04:23","date_gmt":"2021-03-02T21:04:23","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=448812"},"modified":"2021-03-02T16:04:23","modified_gmt":"2021-03-02T21:04:23","slug":"navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\/","title":{"rendered":"Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference<\/b><\/p>\n<p>DUBLIN, Ohio&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nNavidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (\u201cNavidea\u201d or the \u201cCompany\u201d), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announces that management will present a company overview and hold virtual meetings with investors at the H.C. Wainwright Global Life Sciences Virtual Conference being held March 9-10, 2021.\n<\/p>\n<p>\nThe Navidea presentation can be accessed by registering for the H.C. Wainwright Global Life Sciences Virtual Conference <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fhcwevents.com%2Fglobalconference%2F&amp;esheet=52389322&amp;newsitemid=20210302005977&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=0cc8bd530163aeb5756de68969b09c49\">here<\/a>. The webcast will be available on the H.C. Wainwright Conference Portal beginning March 9, 2021 at 7:00 a.m. Eastern time through March 10, 2021 at 9:00 p.m. Eastern time. The Company\u2019s corporate presentation can be accessed from the Investor Relations section of the Company website <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.navidea.com%2F&amp;esheet=52389322&amp;newsitemid=20210302005977&amp;lan=en-US&amp;anchor=here.&amp;index=2&amp;md5=5fbb0f3d7d5795ea76bcd87bbbed2942\">here.<\/a><\/p>\n<p><b>About Navidea <\/b><\/p>\n<p>\nNavidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept\u2122 platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea\u2019s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea\u2019s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company\u2019s pipeline through global partnering and commercialization efforts. For more information, please visit <span class=\"bwuline\"><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.navidea.com&amp;esheet=52389322&amp;newsitemid=20210302005977&amp;lan=en-US&amp;anchor=www.navidea.com&amp;index=3&amp;md5=3e9f331a9fc7f33925233bb6414ec47d\">www.navidea.com<\/a><\/span>.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210302005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210302005977\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210302005977\/en\/<\/a><\/span><\/p>\n<p>\nNavidea Biopharmaceuticals, Inc.<br \/>\n<br \/>Jed Latkin<br \/>\n<br \/>Chief Executive Officer<br \/>\n<br \/>614-973-7490<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jlatkin@navidea.com\">jlatkin@navidea.com<\/a><\/p>\n<p>\nJoel Kaufman<br \/>\n<br \/>Chief Business Officer<br \/>\n<br \/>614-822-2372<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jkaufman@navidea.com\">jkaufman@navidea.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America New York<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology General Health Health Pharmaceutical Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210302005977\/en\/389794\/3\/navidea_cmyk.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference DUBLIN, Ohio&#8211;(BUSINESS WIRE)&#8211; Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (\u201cNavidea\u201d or the \u201cCompany\u201d), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announces that management will present a company overview and hold virtual meetings with investors at the H.C. Wainwright Global Life Sciences Virtual Conference being held March 9-10, 2021. The Navidea presentation can be accessed by registering for the H.C. Wainwright Global Life Sciences Virtual Conference here. The webcast will be available on the H.C. Wainwright Conference Portal beginning March 9, 2021 at 7:00 a.m. Eastern time through March 10, 2021 at 9:00 p.m. Eastern time. The Company\u2019s corporate presentation can be accessed &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-448812","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference DUBLIN, Ohio&#8211;(BUSINESS WIRE)&#8211; Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (\u201cNavidea\u201d or the \u201cCompany\u201d), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announces that management will present a company overview and hold virtual meetings with investors at the H.C. Wainwright Global Life Sciences Virtual Conference being held March 9-10, 2021. The Navidea presentation can be accessed by registering for the H.C. Wainwright Global Life Sciences Virtual Conference here. The webcast will be available on the H.C. Wainwright Conference Portal beginning March 9, 2021 at 7:00 a.m. Eastern time through March 10, 2021 at 9:00 p.m. Eastern time. The Company\u2019s corporate presentation can be accessed &hellip; Continue reading &quot;Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-02T21:04:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210302005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference\",\"datePublished\":\"2021-03-02T21:04:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\\\/\"},\"wordCount\":480,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210302005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\\\/\",\"name\":\"Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210302005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-03-02T21:04:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210302005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210302005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference - Market Newsdesk","og_description":"Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference DUBLIN, Ohio&#8211;(BUSINESS WIRE)&#8211; Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (\u201cNavidea\u201d or the \u201cCompany\u201d), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announces that management will present a company overview and hold virtual meetings with investors at the H.C. Wainwright Global Life Sciences Virtual Conference being held March 9-10, 2021. The Navidea presentation can be accessed by registering for the H.C. Wainwright Global Life Sciences Virtual Conference here. The webcast will be available on the H.C. Wainwright Conference Portal beginning March 9, 2021 at 7:00 a.m. Eastern time through March 10, 2021 at 9:00 p.m. Eastern time. The Company\u2019s corporate presentation can be accessed &hellip; Continue reading \"Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-02T21:04:23+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210302005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference","datePublished":"2021-03-02T21:04:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\/"},"wordCount":480,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210302005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\/","name":"Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210302005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-03-02T21:04:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210302005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210302005977r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-global-life-sciences-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/448812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=448812"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/448812\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=448812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=448812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=448812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}